Tegoprazan - RaQualia Pharma/CJ Healthcare

Drug Profile

Tegoprazan - RaQualia Pharma/CJ Healthcare

Alternative Names: CJ 12420; LXI-15028; RQ-00000004; RQ-4

Latest Information Update: 27 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer CJ Cheiljedang Corp.; CJ HealthCare; RaQualia Pharma
  • Class Antiulcers; Benzimidazoles; Benzopyrans; Fluorobenzenes; Small molecules
  • Mechanism of Action H(+) K(+)-exchanging ATPase inhibitors; Potassium-competitive acid blockers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Erosive oesophagitis; Gastric ulcer; Gastro-oesophageal reflux; Helicobacter infections

Most Recent Events

  • 14 Mar 2018 Shandong Luoxin Pharmaceutical plans a phase I trial in Healthy volunteers in China in April 2018 (NCT03458650)
  • 10 Dec 2017 CJ HealthCare Corporation initiates a phase I trial in Healthy volunteers in South Korea (NCT03378284).
  • 26 Oct 2017 CJ Healthcare plans a phase III trial for Helicobacter infections (In adults, In the elderly, Combination therapy) in South Korea (PO) in October 2017 (NCT03317223)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top